Effectiveness of Pharmaceutical Interventions in Hospitalized Patients

Safety Issues Clinical Trial

— INFAR  

Official title:

Effectiveness of Pharmaceutical Interventions in the Omission of Prescription and Desprescription of Medications in Hospitalized Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04800900
• Other study ID #: 41325820
• Status: Completed
• Phase: N/A
• Start date: February 4, 2021
• Est. completion date: January 30, 2022

Study information

• Verified date: April 2022
• Source: Federal University of Bahia
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The presence of multimorbidities is very common among the elderly, which become major consumers of medicines. The process of prescribing medicines for the elderly should be done with caution, as the use of some medications may present more risks than benefits in this range age. Potentially inappropriate prescribing for the elderly has become a global concern for the promotion of an adequate pharmacotherapy, it becomes essential to be aware of the effectiveness and safety of medicines and the knowledge of which drugs whose risks of serious adverse reactions outweigh the benefit of your referral. In this sense, the present study has aim to evaluate the effectiveness of pharmaceutical interventions in frequency of omission of drugs with proven efficacy for cardiovascular diseases and promotion of treatment prescription inappropriate and polypharmacy. A prospective quasi experimental before and after study will be carried out in elderly patients diagnosed with cardiovascular disease admitted to the Ana Nery hospital, Salvador, Bahia, Brazil. A convenience sample will be collected, the data will be released and revised in a database built in the SPSS software and analyzed in the program statistic R and SPSS. At the end of the study, it is expected a decrease in the frequency of omission of medications and promotion of prescription drugs inappropriate.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 332
• Est. completion date: January 30, 2022
• Est. primary completion date: January 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 60 Years and older

Eligibility

Inclusion Criteria:

• Clinical diagnosis of cardiovascular disease
• Discharge after 24 hours

Exclusion Criteria:

• Death

Related Conditions & MeSH terms

• Safety Issues

Intervention

Other:
• Pharmaceutical intervention
A pharmacist will analyse patient's prescription, identify if there is prescribing omission and inappropriated drug prescribed and when necessary will require to doctors deprescribe or introduce or remove prescribed drugs

Locations

Country	Name	City	State
Brazil	Hospital Ana Nery	Salvador	Bahia

Sponsors (1)

Lead Sponsor	Collaborator
Federal University of Bahia

Country where clinical trial is conducted

Brazil, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Effectiveness of pharmaceutical interventions measured by proportion of accepted interventions and all interventions		The acceptance of all pharmaceutical interventions related to inappropriate prescribed drugs and omission of prescription during the hospitalization of the patient will be evaluated, through study completion, an average of 1 year
Secondary	Incidence of polypharmacy in elderly people with cardiovascular diseases measured by prescription containing five or more drugs		First prescription after 24 hours of admission, last prescription and discharge prescription through study completion, an average of 1 year
Secondary	Incidence of omission of prescription drugs with proven efficacy for cardiovascular diseases measured by the START criteria		First prescription after 24 hours of admission, last prescription and discharge prescription through study completion, an average of 1 year
Secondary	Incidence of potentially inappropriate drug prescription in elderly people with cardiovascular diseases measured by the Beers criteria		First prescription after 24 hours of admission, last prescription and discharge prescription through study completion, an average of 1 year